IN8bio is a clinical-stage biopharmaceutical firm that specializes in advancing gamma-delta T cell therapies to achieve its mission of CANCER ZERO, the safe elimination of all cancer cells in every patient. The company’s DeltEx platform uses allogeneic, autologous, iPSC, and genetically modified approaches to develop novel cell therapies designed to effectively identify and eradicate tumor cells. It has three lead product candidates in clinical trials for glioblastoma and leukemia (INB-400, INB-200, INB-100), and a portfolio of preclinical programs for solid tumors.

For over 20 years, Valos Srl has been seen as a foremost organization in the field of biostatistics and data managment services for Phase I-IV Clinical Trials. With professional experience in drug and device development studies, VALOS offers operational excellence and tailored services while providing high quality research to bolster clients' resounding successes. With a powerhouse team in place, in-depth knowledge of the pharmaceutical and biotech industries and intensive experience, VALOS aims to support its pharma clients set new benchmarks in clinical trials and scale newer heights.

At Jabil, we are proud to be a trusted partner for the world's top brands, offering comprehensive engineering, manufacturing, and supply chain solutions. With over 50 years of experience across industries and a vast network of over 100 sites worldwide, Jabil combines global reach with local expertise to deliver both scalable and customized solutions. Our commitment extends beyond business success as we strive to build sustainable processes that minimize environmental impact and foster vibrant and diverse communities around the globe. Discover more at www.jabil.com.

Elpiscience is a clinical-stage biopharmaceutical company dedicated to developing life-changing immuno-oncology therapies for cancer patients worldwide. The company’s innovative approach is focused on targeting tumor microenvironment to identify effective mechanisms to kill cancer. A pipeline of novel molecules has been developed using its proprietary platforms. Through internal R&D expertise and partnerships with global biopharmaceutical companies, Elpiscience endeavors to advance the programs with breakthrough value into clinic use. To learn more, please visit www.elpiscience.com.

Jumo Health (www.jumohealth.com) creates tailored, highly empathetic educational resources to engage, enroll and retain patients for clinical studies. Covering 24 therapeutic areas and 180 health topics in 120 languages, our human-centered solutions are developed in close collaboration with 150 patient and caretaker communities to incorporate their needs, motivations and concerns, as well as the effects of social determinants of health on their decision making. By creating accessible, relevant and impactful communications for sponsors and sites, Jumo Health empowers patients to take charge of their health, removes barriers to clinical trial participation, and ultimately contributes to better outcomes. For more information, please visit https://jumohealth.com/

Serán is a sci­ence-based CDMO that specializes in a variety of drug delivery and formu­lation strategies suited to optimizing bioavailability. Serán’s experienced formulation team works with customers to identify an appropriate formulation strategy to meet each program’s unique needs with a material-sparing approach. Serán provides capsules, tablets, multi-particulates, and PiB formulations. To learn more, please visit https://www.seranbio.com/

At RPK Medical, we stand out as your long-term partner, experts in crafting tailor-made solutions in the medical device sector. Our commitment goes beyond providing solutions – we aim to transform lives for the better. We prioritize listening to you, understanding your unique needs, and tailoring solutions that go beyond springs, stamping & bending or assemblies with precision and reliability. • 50 years of expertise in creating precision customized parts for security applications • Glocal service: thinking globally, acting locally. Factories in Europe, North America and Asia • Engineering excellence, tailor made for your needs • Customized cleaning and packaging (Clean rooms in Europe, North America and Asia) • A sustainable project, your long-term partner from design to manufacturing. For more information, visit https://rpk-medical.com/en or https://rpk-global.com/medical

Founded in 2012, Slingshot Biosciences is a fast growing life sciences company with a platform technology and paradigm-shifting mission to make synthetic cells the gold standard for all cell-based applications—including diagnostics, adoptive cell therapy development and instrument calibration. Learn more at www.slingshotbio.com

Noble Life Sciences description : Noble is a preclinical CRO based in Sykesville, Maryland, offering GLP and non-GLP services, including safety and efficacy testing, for the development of novel therapeutics. Our Oncology team has deep experience designing and implementing a variety of animal models to characterize oncology drug candidates for efficacy, pharmacodynamics, pharmacokinetics, toxicity, and bioavailability.

Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer. By combining expertise in immunology and immunotherapy, Elicio is engineering investigational AMP immunotherapies intended to precisely target and fully engage the lymph nodes.  ELI-002, a structurally novel investigational AMP therapeutic immunotherapy targeting mutant KRAS-driven solid tumors, is currently in a Phase 2 trial in patients with high relapse risk mKRAS-driven pancreatic cancer.

Cytovation is a clinical-stage immuno-oncology biotech focused on the development of CyPep- 1, a first-in-class synthetic peptide that drives a systemic and cancer-specific immune response. CyPep-1 has a dual mode of action that includes (1) inhibition of the Wnt/beta-catenin oncogenic pathway, and (2) disruption of cancer cell membranes and exposure of neoantigens to the tumor microenvironment. Building on positive data from a 55-patient Ph 1/2a study, Cytovation is focusing on beta-catenin-driven cancers with metastasis to the liver, an area of very high unmet need.